<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2301221626
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GLUCARE XR 500 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METFORMIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Extended-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        28.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Glucare extended &nbsp;release tablets contain the &nbsp;active ingredient &nbsp;metformin &nbsp;hydrochloride &nbsp;and &nbsp; belong to a &nbsp;group of medicines called biguanides, used in the treatment of Type 2 (non‐insulin dependent) diabetes mellitus.</p><p>Glucare XR is &nbsp;used together with &nbsp;diet &nbsp;and &nbsp; exercise to &nbsp;lower &nbsp;the &nbsp; risk &nbsp;of &nbsp;developing Type &nbsp;2 &nbsp;diabetes &nbsp;in overweight adults, when &nbsp;diet &nbsp;and &nbsp;exercise alone for 3 to &nbsp;6 months have not &nbsp;been enough to &nbsp;control blood glucose &nbsp;(sugar). You &nbsp;are &nbsp;at &nbsp;high &nbsp;risk &nbsp;of &nbsp;developing Type &nbsp;2 diabetes if you have additional conditions like high blood pressure, age &nbsp;above 40 years, an abnormal amount of&nbsp;lipids &nbsp; (fat) &nbsp;in &nbsp;the &nbsp; blood or &nbsp;a &nbsp;history &nbsp;of diabetes during pregnancy.<br />The &nbsp;medicine is particularly effective if you &nbsp;are &nbsp;aged below &nbsp;45 years, are &nbsp;very overweight, have high &nbsp;blood glucose levels &nbsp; after &nbsp; a &nbsp;meal &nbsp; or &nbsp;developed diabetes during pregnancy.</p><p>Glucare XR is used for the &nbsp;treatment of Type 2 diabetes when &nbsp;diet &nbsp;and &nbsp;exercise changes alone have not &nbsp; been enough to &nbsp;control blood &nbsp;glucose (sugar). Insulin is a hormone that enables body &nbsp;tissues to take glucose from the &nbsp;blood and &nbsp;to use &nbsp;it for energy or for storage for future use. &nbsp;People with Type 2 diabetes do not make enough insulin in their pancreas or their body does not &nbsp;respond properly to the &nbsp;insulin &nbsp;it does make. This causes a buildup of glucose in the blood which can cause a &nbsp;number of serious long‐term problems so&nbsp; it is important that you continue to take your medicine, even though you may not have any obvious symptoms. Glucare XR makes the body more sensitive to insulin and helps return to normal the way your body uses glucose.<br />Glucare XR is associated with either a stable body weight or modest weight loss.<br />Glucare XR Tablets are specially made to release the drug slowly in your body and therefore are different to many other types of tablet containing metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Glucare XR if:</strong></p><ul><li>&nbsp;You are allergic to metformin or to any of the other ingredients of this medicine (listed in section 6).</li></ul><p>An allergic reaction may cause a rash, itching or shortness of breath.</p><ul><li>You have liver problems.</li><li>You have severely reduced kidney function Sympathomimetic medicines including epinephrine and dopamine used to treat heart attacks and low blood pressure. Epinephrine is also included in some dental anesthetics.</li><li>Medicines that may change the amount of Glucare XR in your blood, especially if you have reduced kidney function (such as verapamil, rifampicin, cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, crizotinib, olaparib).</li></ul><p><strong>Glucare XR with alcohol</strong><br />Avoid excessive alcohol intake while taking Glucare XR since this may increase the risk of lactic acidosis (see section &lsquo;Warnings and precautions&rsquo;).<br /><strong>Pregnancy and breast‐feeding</strong><br />Do not take Glucare XR if you are pregnant or breast feeding.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br /><strong>Driving and using machines</strong><br />Glucare XR taken on its own does not cause &lsquo;hypos&rsquo; (symptoms of low blood sugar or hypoglycemia, such as faintness, confusion and increased sweating) and therefore should not affect your ability to drive or use machinery.<br />You should be aware, however, that Glucare XR taken with other antidiabetic medicines can cause hypos, so in this case you should take extra care when driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor may prescribe Glucare XR for you to take on its own, or in combination with other oral antidiabetic medicines or insulin.</p><p>Always take Glucare XR exactly as your doctor has told you.</p><p>You should check with your doctor or pharmacist if you are not sure.</p><p>Swallow the tablets whole with a glass of water, do not chew.</p><p>You should take Glucare XR with food or immediately after meal.<br />&nbsp;</p><p><strong>Recommended dose</strong><br />Usually you will start treatment with 500 milligrams Glucare XR daily. After you have been taking Glucare XR f or about 2 weeks, your doctor may measure your blood sugar and adjust the dose. The maximum daily dose is 2000 milligrams of Glucare XR. If you have reduced kidney function, your doctor may prescribe a lower dose.<br />Normally, you should take the tablets once a day, with your evening meal.</p><p>In some cases, your doctor may recommend that you take the tablets twice a day. Always take the tablets with food.<br />you may see some remains of the tablets in your stools. don&rsquo;t worry - this is normal for this type of tablets<br />&nbsp;</p><p><strong>If you take more Glucare XR than you should</strong><br />If you take extra tablets by mistake you need not worry, but if you have unusual symptoms, contact your doctor. If the overdose is large, lactic acidosis is more likely. Symptoms of lactic acidosis are non‐specific, such as vomiting, bellyache with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing. Further symptoms are reduced body temperature and heartbeat.</p><p>If you experience some of these symptoms, you should immediately seek medical attention, as lactic acidosis may lead to coma. Stop taking Glucare XR immediately and contact a doctor or the nearest hospital straightaway.<br />&nbsp;</p><p><strong>If you forget to take Glucare XR</strong><br />Take it as soon as you remember with some food. Do not take a double dose to make up for a forgotten dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Glucare XR can cause side effects, although not everybody gets them. The following side effects may occur:<br />Glucare XR may cause a very rare (may affect up to 1 user in 10,000) but very serious side effect called lactic acidosis (see section &lsquo;Warnings and Precautions&rsquo;). If this happens, you must stop taking Glucare XR and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma.<br />Glucare XR may cause abnormal liver function tests and hepatitis (inflammation of the liver) which may result in jaundice (may affect up to 1 user in 10,000). If you develop yellowing of the eyes and/or skin contact your doctor immediately.<br />Undesirable effects:<br />the following adverse reactions were reported in &ge;1.0% to &le; 5.0% of metformin XR patients and were more commonly reported with metformin XR than placebo: abdominal pain, constipation, distention abdomen, hyperacidity/heartburn, flatulence, dizziness, headache, upper respiratory infection, taste disturbance.<br />possible side effects are listed by frequency as follows:<br /><em>Very common (affects more than 1 person in 10):</em></p><ul><li>Diarrhea, nausea, vomiting, stomach ache or loss of appetite. If you get these, do not stop taking the tablets as these symptoms will normally go away in about 2 weeks. It helps if you take the tablets with or immediately after a meal.</li></ul><p><em>Common (affects less than 1 person in 10, but more than 1 person in 100):</em></p><ul><li>&nbsp;Taste disturbance</li></ul><p><em>Very rare (affects less than 1 person in 10,000):</em></p><ul><li>Decreased vitamin B12 levels</li><li>Skin rashes including redness, itching and hives.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not store above 30&deg;C.<br />Do not use Glucare XR after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.<br />This medicinal product does not require any special storage conditions.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Content of Pack and further Information What Glucare XR tablet contain<br />Glucare XR 500 mg tablet<br />The active substance is Metformin hydrochloride. Contains 500 mg of Metformin hydrochloride.<br />Glucare XR 750 mg tablet<br />The active substance is Metformin hydrochloride. Contains 750 mg of Metformin hydrochloride.<br />Glucare XR 1000 mg tablet<br />The active substance is Metformin hydrochloride. Contains 1000 mg of Metformin hydrochloride.<br />The other ingredients for 500 mg and 750 mg: Povidone K30; Magnesium sterate; Colloidal silicon dioxide; hydroxypropyl methylcellulose (hpmc).<br />The other ingredients for 1000 mg: Povidone K30; copovidone; Magnesium sterate; Colloidal silicon dioxide; hydroxypropyl methylcellulose (hpmc).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Glucare XR 500 mg tablet is White to off‐white capsule shape concave tablet embossed with ‘JI172’ on one side.
Pack size: 30 or 60 or 90 Tablets.
Glucare XR 750 mg tablet is White to off‐white capsule shape concave tablet embossed with ‘JI173’ on one side.
Pack size: 30 or 60 Tablets.
Glucare XR 1000 mg tablet is White to off‐white oval shape concave tablets embossed with ‘JI 174’ on one side.
Pack size: 60 Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder and Manufacturer for</p><p>Glucare XR 500, 750 and 1000 mg tablets are held by<br />Jazeera Pharmaceutical Industries (JPI)<br />Riyadh, Saudi Arabia, 11666 Riyadh,<br />P.O.Box 106229<br />Telephone No.: +966‐11‐207‐8172<br />Fax: +966‐11‐207‐8097</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>&nbsp; &nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>&nbsp; &nbsp; Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 9/2017, version3.0
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">جلوكير إكس آر هو أقراص ممتدة المفعول تحتوي على هيدروكلوريد الميتفورمين كمادة فعالة والذي ينتمي إلى مجموعة أدوية تسمى بيغوانيد والمستخدمة في علاج النوع 2 من مرض السكري (غيرمعتمد على الانسولين).</p><p dir="RTL">يستخدم جلوكير إكس آر مع التمارين الرياضية والحمية لتقليل احتمال الاصابة بالسكري من النوع 2 لدى البالغين أصحاب الوزن الزائد، وذلك إذا لم تسيطر الحمية والتمارين الرياضية وحدها بعد 3 إلى 6 شهور على الجلوكوز (السكر) في الدم. أنت معرض بشكل كبير للإصابة بمرض السكري من النوع 2 إذا كانت لديك حالات أخرى مثل ضغط الدم المرتفع، فوق 40 سنة، ومقدار غير عادي من الدهون (الشحوم) في الدم أو تاريخ من مرض السكري أثناء الحمل.</p><p dir="RTL">هذا الدواء فعال بشكل خاص إذا كنت أقل من 45 عاما، مع وزن زائد بدرجة كبيرة، ولديك مستوى مرتفع من الجلوكوز في الدم بعد الوجبات أو عند حدوث السكري أثناء الحمل. يستخدم جلوكير إكس آر لعلاج النوع 2 من السكري عندما تكون الحمية والتمارين كافية للسيطرة على الجلوكوز (السكر) في الدم.</p><p dir="RTL">الانسولين هو هرمون يمكن خلايا الجسم من الحصول على الجلوكوزمن الدم واستخدامه للطاقة أو لتخزينه للاستخدام لاحقا.</p><p dir="RTL">والاشخاص المصابون بالنوع 2 من السكري لا يفرزون الانسولين الكافي من البنكرياس أو لا يستجيب جسدهم بالشكل المناسب للأنسولين الذي يصنعه البنكرياس. وهذا يؤدي إلى تراكم الجلوكوز في الدم والذي يمكن أن يسبب عددا من المشكلات الخطيرة على المدى البعيد، ولذا ؛ فمن المهم مواصلة تناول علاجك حتى إذا لم يكن لديك أعراض واضحة. جلوكير إكس آر يجعل الجسد حساسا تجاه الانسولين ويساعد في العودة إلى الطريقة المعتادة التي يستخدم بها جسدك الجلوكوز.</p><p>جلوكير إكس آر مرتبط بالحفاظ على وزن ثابت للجسم أو خسارة الوزن. تمت صناعة أقراص جلوكير إكس آر بشكل خاص لإفراز الدواء في جسدك ببطء وبالتالي فهو مختلف عن العديد من الأنواع الاخرى للاقراص المحتوية على ميتفورمين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم جلوكير إكس آر في هذه الحالات:</p><ul dir="rtl"><li>&nbsp;إذا كنت تعاني من حساسية تجاه ميتفورمين أو أي من المواد الاخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;قد يؤدي رد الفعل التحسسي إلى حدوث طفح، أو حكة او ضيق النفس.</li><li>تعاني من مشكلات في الكبد</li><li>&nbsp;إذا كان لديك قصور شديد في وظائف الكلى أدوية محاكي الودي بما في ذلك الابينفرين والدوبامين المستخدمة لعلاج مشاكل القلب وانخفاض ضغط الدم. ويدخل الابينفرين أيضا في بعض مخدر الاسنان.</li><li>&nbsp;الادوية التي قد تغير من مقدار جلوكير إكس آر في دمك، وخاصة إذا كان لديك قصور في وظائف الكلى (مثل فيرباميل، وريفامبيسين، وسيميتيدين، ودولوتيجرافير، ورانولازين، وتريميثوبريم، وفانديتانيب، واسافوكونازول، وكريزوتينيب، وأولاباريب).</li></ul><p dir="RTL"><strong>جلوكير إكس آر مع الكحول</strong></p><p dir="RTL">تجنب الكحول أو الادوية التي تحتوي على الكحول عند تناول جلوكير إكس آر لان الكحول قد يزيد من خطر الحماض اللاكتيكي (انظر القسم 2&nbsp;من الاحتياطات والتحذيرات).</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">لا تتناولي جلوكير إكس آر قبل استشارة طبيبك إذا كنت حامل أو مرضع. استشيري طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL"><strong>تأثير جلوكير إكس آر على القيادة واستخدام الالات</strong></p><p dir="RTL">تناول جلوكير إكس آر وحده لا يسبب &quot;هبوطا &quot; (أعراض انخفاض سكر الدم، كالاغماء، والاضطراب، والتعرق الزائد) ولذا يجب الا <strong>تتأثر قدرتك على القيادة أو استخدام الالات</strong><strong>.</strong> &nbsp;&nbsp;</p><p dir="RTL">ومع هذا، ينبغي أن تدرك أنه عند تناول جلوكير إكس آر مع أدوية أخرى مضادة للسكري فإن هذا قد يسبب هبوطا، وفي هذه الحالة ينبغي زيادة الحذر أثناء القيادة وتشغيل الالات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">قد يصف لك طبيبك جلوكير إكس آر كي تتناوله وحده أو مع أدوية أخرى مضادة للسكري عن طريق الفم أو مع الانسولين. قم دائما بتناول جلوكير إكس آر كما هو مذكور في هذه النشرة أو كما وصفه لك طبيبك أو الصيدلي تماما.</p><p dir="RTL" style="text-align:justify">تحقق من طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL" style="text-align:justify">ابتلع القرص كاملا مع كوب من الماء، لا تمضغه.</p><p dir="RTL" style="text-align:justify">يجب أخذ جلوكير إكس آر مع الوجبة أو بعدها مباشرة.</p><p dir="RTL" style="text-align:justify">في حالة وجود بقايا للقرص في البراز - لا داعي للقلق - هذا من الطبيعي عند استخدام هذا النوع من الأقراص الممتدة المفعول.</p><p dir="RTL"><strong>الجرعة الموصى بها هي</strong><strong>:</strong></p><p dir="RTL" style="text-align:justify">عليك في العادة أن تبدأ العلاج بمقدار 500 مليغرام من جلوكير إكس آر يوميا. بعد تناول جلوكير إكس آر لمدة أسبوعين متتاليين، قد يقيس طبيبك مستوى السكر في الدم لديك ويعدل الجرعة. إن الجرعة اليومية القصوى هي 2000 ملليغرام من جلوكير إكس آر.</p><p dir="RTL" style="text-align:justify">إذا كان لديك قصور في وظائف الكلى، فقد يصف لك طبيبك جرعة أقل. في العادة عليك تناول الاقراص مرة في اليوم، مع وجبة المساء.</p><p dir="RTL" style="text-align:justify">في بعض الحالات، قد ينصحك طبيبك بتناول الاقراص مرتين في اليوم. من الافضل تناول الاقراص مع الطعام.</p><p dir="RTL" style="text-align:justify"><strong>إذا تناولت جرعة زائدة من جلوكير إكس آر</strong></p><p dir="RTL" style="text-align:justify">إذا تناولت أقراصا إضافية بالخطأ، فلا تقلق، لكن اتصل بطبيبك إذا ظهرت لديك أعراض غير طبيعية. إذا كانت الجرعة الزائدة كبيرة، فعلى الارحج سيحدث الُحماض اللاكتيكي. وأعراض الُحماض اللاكتيكي غير محددة، كالقيء، وألم البطن مع تقلصات عضلية، وشعور عام بعدم الارتياح مع تعب حاد، وصعوبة في التنفس. وهناك أعراض أخرى وهي انخفاض درجة حرارة الجسم وضربات القلب. إذا كانت لديك أي من هذه الاعراض، فيجب أن تبحث عن مساعدة طبية عاجلة لأن الُحماض اللاكتيكي قد يؤدي إلى غيبوبة. توقف عن تناول جلوكير إكس آر واتصل بالطبيب على الفور أو اذهب إلى أقرب مستشفى.</p><p dir="RTL" style="text-align:justify"><strong>إذا نسيت تناول جلوكير إكس آر</strong></p><p dir="RTL" style="text-align:justify">تناول الدواء وقتما تتذكر مع شيء من الطعام. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الادوية، قد يسبب جلوكير إكس آر آثارا جانبية، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء. قد تحدث الآثار الجانبية التالية:</p><p dir="RTL">قد يسبب جلوكير إكس آر تأثيرا جانبيا نادرا للغاية (قد يؤثر على ما يصل إلى شخص واحد من كل 10000 شخص) والذي يُسمى الُحماض اللاكتيكي (انظر قسم الاحتياطات والتحذيرات). إذا حدث هذا، فتوقف عن تناول جلوكير إكس آر واتصل بالطبيب أو اذهب إلى أقرب مستشفى على الفور، لان الحماض اللاكتيكي قد يؤدي إلى غيبوبة.</p><p dir="RTL">قد يتسبب جلوكير إكس آر في نتائج غير منتظمة لوظائف الكبد والتهاب الكبد (تضخم الكبد) والذي قد يؤدي إلى يرقان (قد يؤثر على ما يصل إلى شخص من كل 10000). إذا حدث اصفرار في العين أو في الجلد، فاتصل بطبيبك على الفور.</p><p dir="RTL">الآثار الجانبية التالية تم التبليغ عنها في أكثر من 1٪ وأقل من 5٪ من مستخدمي الميتفورمين ممتد المفعول.</p><p dir="RTL">ألم المعدة، الإمساك، الانتفاخ، حموضة/حرقة، دوخة، صداع، إلتهاب الجهاز التنفسي العلوي، اضطراب في حاسة التذوق.</p><p dir="RTL">الآثار الجانبية المحتملة حسب التكرار هي كما يلي:</p><p dir="RTL"><em>شائعة جد ا (تؤثر على أكثر من 1 من كل 10 أشخاص</em><em>):</em></p><ul dir="rtl"><li>الإسهال، أو الغثيان، أو القيء، أو ألم المعدة أو فقدان الشهية. إذا كانت لديك تلك الاعراض، فلا تتوقف عن تناول الأقراص فهذه الاعراض سوف تزول عادة في غضون أسبوعين. من الافضل تناول الاقراص مع الوجبة أو بعدها على الفور.</li></ul><p dir="RTL"><em>شائعة (تؤثر على أقل من 1 من كل 10 أشخاص، لكن تؤثر في أكثرمن 1 من كل 100 شخ</em><em>ص):</em><em> </em><em>&nbsp;</em><em>&nbsp;</em></p><ul dir="rtl"><li>&nbsp;اضطرابات في حاسة التذوق</li></ul><p dir="RTL"><em>آثار جانبية نادرة جدا (تؤثر على أقل من شخص من كل 10000 شخص</em><em>)</em><em>:</em></p><ul dir="rtl"><li>&nbsp;مستويات منخفضة من فيتامين B12</li><li>طفح جلدي يشمل الاحمرار، والحكة، والارتيكاريا.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدا عن مرأى ومتناول الاطفال.</p><p dir="RTL">لا يحفظ عند درجة حرارة أعلى من 30 &deg; مئوية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة.</p><p dir="RTL">يشير تاريخ الانتهاء إلى اليوم الاخير من ذلك الشهر.</p><p dir="RTL">لا يحتاج هذا المنتج الدوائي إلى ظروف تخزين خاصة.</p><p dir="RTL">لا تتخلص من الادوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الادوية التي لم تعد بحاجة إليها. اتبع هذه الاجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">محتويات قرص جلوكير إكس آر</p><p dir="RTL" style="text-align:justify"><em>جلوكير إكس آر 500 ملغم أقراص</em></p><p dir="RTL" style="text-align:justify">المادة الفعالة هي هيدروكلوريد ميتفورمين. يحتوي كل قرص على500 ملغم من هيدروكلوريد الميتفورمين.</p><p dir="RTL" style="text-align:justify"><em>جلوكير إكس آر 750 ملغم أقراص</em></p><p dir="RTL" style="text-align:justify">المادة الفعالة هي هيدروكلوريد الميتفورمين. يحتوي كل قرص على750 ملغم من هيدروكلوريد ميتفورمين.</p><p dir="RTL" style="text-align:justify"><em>جلوكير إكس آر 1000 ملغم أقراص</em></p><p dir="RTL" style="text-align:justify">المادة الفعالة هي هيدروكلوريد الميتفورمين. يحتوي كل قرص على1000 ملغم من هيدروكلوريد ميتفورمين.</p><p dir="RTL" style="text-align:justify">مكونات أخرى بتركيز 500 و 750 ملغم: بوفيدون k30، سترات الماغنيسيوم، ثاني أكسيد السيليكون الغرواني، ميثيل سيلُولوز هيدروكسي بروبيل.</p><p dir="RTL" style="text-align:justify">مكونات أخرى بتركيز 1000 ملغم: بوفيدون k30، كوبوفيدون، سترات الماغنيسيوم، ثاني أكسيد السيليكون الغرواني، ميثيل سيلُولوز هيدروكسي بروبيل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL" style="text-align:right"><em>أقراص جلوكير إكس آر بتركيز تركيز 500 ملغم</em> هي أقراص كبسولية بلون أبيض يميل إلى العاجي مطبوعا عليها &laquo;JI172&raquo; على أحد الجانبين.</p><p dir="RTL" style="text-align:right">حجم العبوة: 30 ، أو 60 ، أو 90 قرصا.</p><p dir="RTL" style="text-align:right"><em>أقراص جلوكير إكس آر بتركيز 750 ملغم</em> هي أقراص كبسولية بلون أبيض يميل إلى العاجي مطبوعا عليها &laquo;JI173&raquo; على أحد الجانبين.</p><p dir="RTL" style="text-align:right">حجم العبوة: 30 أو 60 قرصا.</p><p dir="RTL" style="text-align:right"><em>أقراص جلوكير إكس بتركيز 1000 ملغم</em> هي أقراص كبسولية بلون أبيض يميل إلى العاجي مطبوعا عليها &laquo;JI174&raquo; على أحد الجانبين.</p><p dir="RTL" style="text-align:right">حجم العبوة: 60 قرصا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اسم وعنوان مالك رخصة التسويق لاقراص جلوكير إكس آر</p><p dir="RTL">&nbsp;&nbsp;500 ، و 750 ، و 1000 ملغم هو الجزيرة للصناعات الدوائية(JPI)</p><p dir="RTL">11666 الرياض، صندوق بريد 106229</p><p dir="RTL">هاتف رقم: 8172-207-11-966+</p><p dir="RTL">فاكس:7662-205-11-966+</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه).&nbsp;من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul><li dir="RTL">&nbsp; &nbsp; المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul><li dir="RTL">&nbsp; &nbsp; دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم مراجعة هذه النشرة بتاريخ 2017/09؛ رقم النسخة SA3.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Glucare® 500 mg Extended‐Release Tablet (Metformin Hydrochloride)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each one extended release tablet contains 500mg metformin hydrochloride.
For a full list of excipients (See Section 6.1. Liace.st of excipients)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White to off‐white capsule shape concave tablet embossed with ‘JI172’ on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT* and/or IFG*, and/or increased HbA1C who are:<br />‐ At high risk for developing overt type 2 diabetes mellitus (see section 5.1) and<br />‐ Still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.</p><p>Treatment with Glucare XR must be based on a risk score incorporating appropriate measures of glycemic control and including evidence of high cardiovascular risk (see section 5.1).<br />Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.<br />*IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose</p><ul><li>Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycemic control. Glucare XR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Adults with normal renal function (GFR &ge; 90 mL/min) Reduction in the risk or delay of the onset of type 2 diabetes</p><ul><li>Metformin should only be considered where intensive lifestyle modifications for 3 to 6 months have not resulted in adequate glycemic control.</li><li>The therapy should be initiated with one tablet Glucare XR 500 mg once daily with the evening meal.</li><li>After 10 to 15 days dose adjustment on the basis of blood glucose measurements is recommended (OGTT and/or FPG and/or HbA1C values to be within the normal range). A slow increase of dose may improve gastro‐intestinal tolerability. The maximum recommended dose is 4 tablets (2000 mg) once daily with the evening meal.</li><li>It is recommended to regularly monitor (every 3‐6 months) the glycemic status (OGTT and/or FPG and/or HbA1c value) as well as the risk factors to evaluate whether treatment needs to be continued, modified or discontinued.</li><li>A decision to re‐evaluate therapy is also required if the patient subsequently implements improvements to diet and/or exercise, or if changes to the medical condition will allow increased lifestyle interventions to be possible.</li></ul><p>Monotherapy in Type 2 diabetes mellitus and combination with other oral antidiabetic agents:</p><ul><li>The usual starting dose is one tablet of Glucare XR500 mg once daily.</li><li>After 10 to 15 days the dose should be adjusted based on blood glucose measurements. A slow increase of dose may improve gastro‐intestinal tolerability. The maximum recommended dose is 4 tablets daily.</li><li>Dosage increases should be made in increments of 500mg every 10‐15 days, up to a maximum of 2000mg once daily with the evening meal. If glycemic control is not achieved on Glucare XR2000mg once daily, Glucare XR1000mg twice daily should be considered, with both doses being given with food. If glycemic control is still not achieved, patients may be switched to standard metformin tablets to a maximum dose of 3000 mg daily.</li><li>In patients already treated with metformin tablets, the starting dose of Glucare XR should be equivalent to the daily dose of metformin immediate release tablets. In patients treated with metformin at a dose above 2000 mg daily, switching to Glucare XR is not recommended.</li><li>If transfer from another oral antidiabetic agent is intended: discontinue the other agent and initiate Glucare XR at the dose indicated above.</li><li>Glucare XR750 mg and Glucare XR1000 mg are intended for patients who are already treated with metformin tablets (prolonged or immediate release).</li><li>The dose of Glucare XR750 mg or Glucare XR1000 mg should be equivalent to the daily dose of metformin tablets (prolonged or immediate release), up to a maximum dose of 1500 mg or 2000 mg respectively, given with the evening meal.</li></ul><p>Combination with insulin</p><p>Metformin and insulin may be used in combination therapy to achieve better blood glucose control. The usual starting dose of Glucare XR s one 500 mg tablet once daily, while insulin dosage is adjusted on the basis of blood glucose measurements.</p><p>For patients already treated with metformin and insulin in combination therapy, the dose of Glucare XR750 mg or Glucare XR1000 mg should be equivalent to the daily dose of metformin tablets up to a maximum of 1500 mg or 2000 mg respectively, given with the evening meal, while insulin dosage is adjusted based on blood glucose measurements.</p><p><em>Elderly</em></p><p>Due to the potential for decreased renal function in elderly subjects, the metformin dosage should be adjusted based on renal function. Regular assessment of renal function is necessary (see section 4.4).</p><p>Benefit in the reduction of risk or delay of the onset of type 2 diabetes mellitus has not been established in patients 75 years and older (see section 5.1) and metformin initiation is therefore not recommended in these patients (see section 4.4).</p><p><em>Renal impairment</em></p><p>A GFR should be assessed before initiation of treatment with metformin containing products and at least annually thereafter. In patients at an increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3‐6 months.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>GFR (mL/min)</p></td><td><p>Total maximum daily dose</p></td><td><p>Additional considerations</p></td></tr><tr><td><p>60‐89</p></td><td><p>2000 mg</p></td><td><p>Dose reduction may be considered in relation to declining renal function.</p></td></tr><tr><td><p>45‐59</p></td><td><p>2000 mg</p></td><td><p>Factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of metformin.</p></td></tr><tr><td><p>30‐44</p></td><td><p>1000 mg</p></td><td><p>The starting dose is at most half of the maximum dose.</p></td></tr><tr><td><p>&lt;30</p></td><td><p>‐</p></td><td><p>Metformin is contraindicated.</p></td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1"><tbody></tbody></table><p><em>Pediatric population</em></p><p>In the absence of available data, Glucare XR should not be used in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to metformin or to any of the excipients listed in section 6.1.
•	Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis)
•	Diabetic pre‐coma
•	Severe renal failure (GFR < 30 mL/min).
•	Acute conditions with the potential to alter renal function such as:
−	dehydration,
−	severe infection,
−	shock
•	Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as:
−	decompensated heart failure,
−	respiratory failure,
−	recent myocardial infarction,
−	shock
•	Hepatic insufficiency, acute alcohol intoxication, alcoholism

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Lactic acidosis</u>:</p><p>Lactic acidosis, a very rare, but serious, metabolic complication, most often occurs at acute worsening of renal function or cardiorespiratory illness or sepsis. Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis.</p><p>In case of dehydration (severe diarrhea or vomiting, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended. Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and NSAIDs) should be initiated with caution in metformin‐treated patients. Other risk factors for lactic acidosis are excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis (see sections 4.3 and 4.5).</p><p>Patients and/or care‐givers should be informed of the risk of lactic acidosis. Lactic acidosis is characterized by acidotic dyspnea, abdominal pain, muscle cramps, asthenia and hypothermia followed by coma. In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention. Diagnostic laboratory findings are decreased blood pH (&lt; 7.35), increased plasma lactate levels (&gt;5 mmol/L) and an increased anion gap and lactate/pyruvate ratio.</p><p><u>Renal function</u>:</p><p>GFR should be assessed before treatment initiation and regularly thereafter, see section 4.2.</p><p>Metformin is contraindicated in patients with GFR&lt;30 mL/min and should be temporarily discontinued in the presence of conditions that alter renal function, see section 4.3.</p><p><u>Cardiac function</u></p><p>Patients with heart failure are more at risk of hypoxia and renal insufficiency. In patients with stable chronic heart failure, metformin may be used with a regular monitoring of cardiac and renal function.</p><p>For patients with acute and unstable heart failure, metformin is contraindicated (see section 4.3).</p><p>Elderly:</p><p>Due to the limited therapeutic efficacy data in the reduction of risk or delay of type 2 diabetes in patients 75 years and older, metformin initiation is not recommended in these patients.</p><p><u>Administration of iodinated contrast agents</u>:</p><p>Intravascular administration of iodinated contrast agents may lead to contrast induced nephropathy, resulting in metformin accumulation and an increased risk of lactic acidosis. Metformin should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re‐evaluated and found to be stable, see sections 4.2 and 4.5.</p><p><u>Surgery</u>:</p><p>Metformin must be discontinued at the time of surgery under general, spinal or epidural anesthesia. Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re‐evaluated and found to be stable.</p><p><u>Other precautions</u>:</p><p>All patients should continue their diet with a regular distribution of carbohydrate intake during the day. Overweight patients should continue their energy‐restricted diet.</p><p>The usual laboratory tests for diabetes monitoring should be performed regularly. Metformin alone never causes hypoglycemia, although caution is advised when it is used in combination with insulin or other oral antidiabetics (e.g. sulphonylureas or meglitinides).</p><p>The tablet shells may be present in the faeces. Patients should be advised that this is normal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Concomitant use not recommended</u></p><p><em>Alcohol</em></p><p>Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in case of fasting, malnutrition or hepatic impairment.</p><p><em>Iodinated contrast agents</em></p><p>Metformin must be discontinued prior to or at the time of the imaging procedure and not</p><p>restarted until at least 48 hours after, provided that renal function has been re‐evaluated and found to be stable, see sections 4.2 and 4.4.</p><p><u>Combinations requiring precautions for use</u></p><p>Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo‐oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. When starting or using such products in combination with metformin, close monitoring of renal function is necessary.</p><p><em>Medicinal products with intrinsic hyperglycemic activity (e.g. glucocorticoids (systemic and local routes) and sympathomimetics).</em></p><p>More frequent blood glucose monitoring may be required, especially at the beginning of treatment. If necessary, adjust the metformin dosage during therapy with the other drug and upon its discontinuation.</p><p><em>Organic cation transporters (OCT)</em></p><p>Metformin is a substrate of both transporters OCT1 and OCT2.</p><p>Co‐administration of metformin with</p><ul><li>Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.</li><li>&nbsp; Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin.</li><li>Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration.</li><li>Inhibitors of both OCT1 and OCT2 (such as crizotinib, olaparib) may alter efficacy and renal elimination of metformin.</li></ul><p>Caution is therefore advised, especially in patients with renal impairment, when these drugs are co‐administered with metformin, as metformin plasma concentration may increase. If needed, dose adjustment of metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy Category B</strong></p><p><u>Pregnancy</u></p><p>Uncontrolled diabetes during pregnancy (gestational or permanent) is associated with increased risk of congenital abnormalities and perinatal mortality.</p><p>A limited amount of data from the use of metformin in pregnant women does not indicate an increased risk of congenital abnormalities. Animal studies do not indicate harmful effects with respect to pregnancy, embryonic or fetal development, parturition or postnatal development (see section 5.3).</p><p>When the patient plans to become pregnant and during pregnancy, it is recommended that impaired glycemic control or diabetes are not treated with metformin. For diabetes it is recommended that insulin should be used to maintain blood glucose levels as close to normal as possible to reduce the risk of malformations of the fetus.</p><p><u>Breast‐feeding</u></p><p>Metformin is excreted into human breast milk. No adverse effects were observed in breastfed newborns/infants. However, as only limited data are available, breastfeeding is not recommended during metformin treatment. A decision on whether to discontinue breast‐feeding should be made, taking into account the benefit of breast‐feeding and the potential risk to adverse effect on the child.</p><p><u>Fertility</u></p><p>Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately three times the maximum recommended human daily dose based on body surface area comparisons.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metformin monotherapy does not cause hypoglycemia and therefore has no effect on the ability to drive or to use machines.</p><p>However, patients should be alerted to the risk of hypoglycemia when metformin is used in combination with other antidiabetic agents (e.g. sulphonylureas, insulin, or meglinitides).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In post marketing data and in controlled clinical studies, adverse event reporting in patients</p><p>treated with metformin extended release was similar in nature and severity to that reported in patients treated with metformin immediate release.</p><p>During treatment initiation, the most common adverse reactions are nausea, vomiting, diarrhea, abdominal pain and loss of appetite, which resolve spontaneously in most cases.</p><p>The following adverse reactions may occur with metformin.</p><p>Frequencies are defined as follows: very common: &gt;1/10; common &ge;1/100, &lt;1/10; uncommon</p><p>&ge;1/1,000, &lt;1/100; rare &ge;1/10,000, &lt;1/1,000; very rare &lt;1/10,000.</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>Metabolism and nutrition disorders</p><p>Very rare:</p><ul><li>Lactic acidosis (see 4.4. Special warnings and precautions for use).</li><li>Decrease of vitamin B12 absorption with decrease of serum levels during long‐term use of metformin. Consideration of such an aetiology is recommended if a patient presents with megaloblastic anaemia.</li></ul><p>Nervous system disorders</p><p>Common:</p><ul><li>Taste disturbance</li></ul><p>Gastrointestinal disorders</p><p>Very common:</p><ul><li>Gastrointestinal disorders such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite. These undesirable effects occur most frequently during initiation of therapy and resolve spontaneously in most cases. A slow increase of the dose may also improve gastrointestinal tolerability.</li></ul><p>Hepatobiliary disorders</p><p>Very rare</p><ul><li>Isolated reports of liver function tests abnormalities or hepatitis resolving upon metformin discontinuation.</li></ul><p>Skin and subcutaneous tissue disorders</p><p>Very rare:</p><ul><li>Skin reactions such as erythema, pruritus, urticaria</li></ul><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p><strong>&nbsp;</strong>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>To report side effects:</p><ul><li>&nbsp;&nbsp;<strong>Saudi Arabia:</strong></li></ul><p>&minus; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966‐11‐205‐7662 Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>Toll free phone: 8002490000</p><p>E‐mail:<u> npc.drug@sfda.gov.sa</u></p><p>Website: <u>www.sfda.gov.sa/npc</u></p><ul><li><strong>Other GCC States: </strong>Please contact the relevant competent authority.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypoglycemia has not been seen with metformin doses of up to 85 g, although lactic acidosis has occurred in such circumstances. High overdose or concomitant risks of metformin may lead to lactic acidosis. Lactic acidosis is a medical emergency and must be treated in hospital. The most effective method to remove lactate and metformin is hemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ORAL ANTI‐DIABETICS</p><p>(A10BA02: Gastrointestinal tract and metabolism)</p><p>Metformin is a biguanide with antihyperglycemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycemia.</p><p>Mechanism of action</p><p>Metformin may act via 3 mechanisms:</p><ul><li>reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis</li><li>in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilisation</li><li>and delay of intestinal glucose absorption.</li></ul><p>Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase.</p><p>Metformin increases the transport capacity of all types of membrane glucose transporters (GLUT). Pharmacodynamic effects</p><p>In clinical studies, the major non glycemic effect of metformin is either weight stability or modest weight loss.</p><p>In humans, independently of its action on glycaemia, immediate release metformin has favourable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium‐term or long‐term clinical studies: immediate release metformin reduces total cholesterol, LDL cholesterol and triglyceride levels. A similar action has not been demonstrated with the prolonged release formulation, possibly due to the evening administration, and an increase in triglycerides may occur.</p><p>Clinical efficacy:</p><p>Reduction in the risk or delay of type 2 diabetes mellitus</p><p>The Diabetes Prevention Program (DPP) was a multicenter randomized controlled clinical trial in adults assessing the efficacy of an intensive lifestyle intervention or metformin to prevent or delay the development of type 2 diabetes mellitus. Inclusion criteria were age &ge;25 years, BMI &ge;24 kg/m2 (&ge;22 kg/m2 for Asian‐Americans), and impaired glucose tolerance plus a fasting plasma glucose of 95 &ndash; 125 mg/dl (or &le;125 mg/dl for American Indians). Patients were either treated with intensive lifestyle intervention, 2x850 mg metformin plus standard lifestyle change, or placebo plus standard lifestyle change.</p><p>The mean baseline values of the DPP participants (n=3,234 for 2.8 years) were age 50.6&plusmn;10.7 years, 106.5&plusmn;8.3 mg/dl fasted plasma glucose, 164.6&plusmn;17.0 mg/dl plasma glucose two hours after an oral glucose load, and 34.0&plusmn;6.7 kg/m2 BMI. Intensive lifestyle intervention as well as metformin significantly reduced the risk of developing overt diabetes compared to placebo, 58% (95% CI 48‐ 66%) and 31% (95% CI 17‐43%), respectively.</p><p>The advantage of the lifestyle intervention over metformin was greater in older persons.</p><p>The patients who benefited most from the metformin treatment were aged below 45 years, with a BMI equal or above 35kg/m2, a baseline glucose 2 h value of 9.6‐11.0 mmol/l, a baseline HbA1C equal or above 6.0% or with a history of gestational diabetes.</p><p>To prevent one case of overt diabetes during the three years in the whole population of the DPP, 6.9 patients had to participate in the intensive lifestyle group and 13.9 in the metformin group. The point of reaching a cumulative incidence of diabetes equal to 50% was delayed by about three years in the metformin group compared to placebo.</p><p>The Diabetes Prevention Program Outcomes Study (DPPOS) is the long‐term follow‐up study of the DPP including more than 87% of the original DPP population for long‐term follow up.</p><p>Among the DPPOS participants (n=2776), the cumulative incidence of diabetes at year 15 is 62% in the placebo group, 56% in the metformin group, and 55% in the intensive lifestyle intervention group. Crude rates of diabetes are 7.0, 5.7 and 5.2 cases per 100 person‐years among the placebo,</p><p>metformin, and intensive lifestyle participants, respectively. Reductions in the diabetes risk were of 18% (hazard ratio (HR) 0.82, 95% CI 0.72&ndash;0.93; p=0.001) for the metformin group and 27% (HR 0.73, 95% CI 0.65&ndash;0.83; p&lt;0.0001) for the intensive lifestyle intervention group, when compared with the placebo group. For an aggregate microvascular endpoint of nephropathy, retinopathy and neuropathy, the outcome was not significantly different between the treatment groups, but among the participants who had not developed diabetes during DPP/DPPOS, the prevalence of the aggregate microvascular outcome was 28% lower compared with those who had developed diabetes (Risk Ratio 0.72, 95% CI 0.63&ndash;0.83; p&lt;0.0001). No prospective comparative data for metformin on macrovascular outcomes in patients with IGT and/or IFG and/or increased HbA1C are available.</p><p>Published risk factors for type 2 diabetes include: Asian or black ethnic background, age above 40, dyslipidaemia, hypertension, obesity or being overweight, age, 1st degree family history of diabetes, history of gestational diabetes mellitus, and polycystic ovary syndrome (PCOS).</p><p>Consideration must be given to current national guidance on the definition of prediabetes. Patients at high risk should be identified by a validated risk‐assessment tool.</p><p>Treatment of type 2 diabetes mellitus</p><p>The prospective randomised (UKPDS) study has established the long‐term benefit of intensive blood glucose control in overweight type 2 diabetic patients treated with immediate release metformin as first‐line therapy after diet failure. Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:</p><ul><li>a significant reduction of the absolute risk of any diabetes‐related complication in the metformin group (29.8 events/ 1000 patient‐years) versus diet alone (43.3 events/ 1000 patient‐years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/ 1000 patient‐years), p=0.0034.</li><li>a significant reduction of the absolute risk of diabetes‐related mortality: metformin 7.5 events/1000 patient‐years, diet alone 12.7 events/ 1000 patient‐years, p=0.017;</li><li>a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/ 1000 patient‐years versus diet alone 20.6 events/ 1000 patient‐years (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/ 1000 patient‐years (p=0.021);</li><li>a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/ 1000 patient‐years, diet alone 18 events/ 1000 patient‐years (p=0.01)</li></ul><p>For metformin used as second‐line therapy, in combination with a sulphonylurea, benefit regarding clinical outcome has not been shown.</p><p>In type 1 diabetes, the combination of metformin and insulin has been used in selected patients,</p><p>but the clinical benefit of this combination has not been formally established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After an oral dose of the prolonged release tablet, metformin absorption is significantly delayed compared to the immediate release tablet with a T<sub>max</sub> at 7 hours (T<sub>max</sub> for the immediate release tablet is 2.5 hours).</p><p>At steady state, similar to the immediate release formulation, C<sub>max</sub> and AUC are not proportionally increased to the administered dose. The AUC after a single oral administration of 2000mg of metformin prolonged release tablets is similar to that observed after administration of 1000mg of metformin immediate release tablets b.i.d.</p><p>Intrasubject variability of C<sub>max</sub> and AUC of metformin prolonged release is comparable to that observed with metformin immediate release tablets.</p><p>When the prolonged release tablet is administered in fasting conditions the AUC is decreased by 30% (both C<sub>max</sub> and T<sub>max</sub> are unaffected).</p><p>Mean metformin absorption from the prolonged release formulation is almost not altered by meal composition.</p><p>No accumulation is observed after repeated administration of up to 2000mg of metformin as prolonged release tablets.</p><p>Following a single oral administration of 1500 mg of metformin extended release, a mean peak plasma concentration of 1193 ng/ml is achieved with a median value of 5 hours and a range of 4 to 12 hours.</p><p>metformin extended release 750 mg was shown to be bioequivalent to metformin extended release 500 mg at a 1500 mg dose with respect to C<sub>max </sub>and AUC in healthy fed and fasted subjects.</p><p>Following a single oral administration in the fed state of one tablet of metformin extended release 1000 mg, a mean peak plasma concentration of 1214 ng/ml is achieved with a median time of 5 hours (range of 4 to 10 hours).</p><p>metformin extended release 1000 mg was shown to be bioequivalent to metformin extended release 500 mg at a 1000 mg dose with respect to C<sub>max</sub> and AUC in healthy fed and fasted subjects.</p><p>When the 1000 mg prolonged release tablet is administered in fed conditions the AUC is increased by 77% (C<sub>max</sub> is increased by 26% and T<sub>max</sub> is slightly prolonged by about 1 hour).</p><p><strong>Distribution</strong></p><p>Plasma protein binding is negligible. Metformin partitions into erythrocytes. The blood peak is lower than the plasma peak and appears at approximately the same time. The red blood cells most likely represent a secondary compartment of distribution. The mean Vd&nbsp; ranged between 63‐276 L.</p><p><strong>Metabolism</strong></p><p>Metformin is excreted unchanged in the urine. No metabolites have been identified in humans.</p><p><strong>Elimination</strong></p><p>Renal clearance of metformin is &gt; 400 ml/min, indicating that metformin is eliminated by</p><p>glomerular filtration and tubular secretion. Following an oral dose, the apparent terminal elimination half‐life is approximately 6.5 hours.</p><p>When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half‐life is prolonged, leading to increased levels of metformin in plasma.</p><p><u>Characteristics in specific groups of patients</u></p><p>Renal impairment</p><p>The available data in subjects with moderate renal insufficiency are scarce and no reliable estimation of the systemic exposure to metformin in this subgroup as compared to subjects with normal renal function could be made. Therefore, the dose adaptation should be made upon</p><p>clinical efficacy/tolerability considerations (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Preclinical data reveal no special hazard for humans based on conventional studies on safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Citric acid anhydrous&nbsp;</p><p>‐ &nbsp;Povidone K30;<br />‐ &nbsp;Magnesium sterate;<br />‐ &nbsp;Purified water;<br />‐ &nbsp;Colloidal silicon dioxide;<br />‐ &nbsp;Hypromellose<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC + PVDC Clear / Aluminum Foil.<br />Available pack size: 30, 60 and 90 tablets.<br />Not all pack sizes may be marketed.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Jazeera Pharmaceutical Industries (JPI)
Riyadh, Saudi Arabia, 11666 Riyadh, P.O.Box 106229
 Telephone No.: +966‐11‐207‐8172
Fax: +966‐11‐207‐8097

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12 Sep 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>